Unregulated or compounded versions of prescription peptides such as semaglutide can contain unverified chemical forms that differ from FDA‑approved formulations, creating safety and quality concerns.
high
safety
Compounded or unregulated peptide products may not match approved chemical specifications and can pose risks.